Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437049 | 0.92 | P2RY2 (0.53) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL1457065 | 0.84 | P2RY2 (0.54) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8814444 | 0.83 | P2RY2 (0.59) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL31381447 | 0.83 | P2RY14 (0.56) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8440653 | 0.83 | P2RY2 (0.54) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8437841 | 0.82 | P2RY2 (0.59) | P2RY2P2RY4P2RY6POLA1 | |
| Cyanide SCHEMBL29185226 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8439076 | 0.81 | P2RY2 (0.55) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL5250418 | 0.81 | SLC28A1 (0.42) | P2RY2P2RY4P2RY6 | |
| SCHEMBL8440331 | 0.80 | P2RY2 (0.53) | P2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444355-A4 | NUCLEIC ACID AMPLIFICATION | QIAGEN GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1444355-A2 | NUCLEIC ACID AMPLIFICATION | Qiagen GmbH (DE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003033724-A2 | NUCLEIC ACID AMPLIFICATION | MOLECULAR STAGING, INC. (US) | 2003-04-24 | — | — | WO | disclosed |